Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: a SEER Population-Based Analysis

Xiaoyi Lin  
Guangdong Provincial People's Hospital  

Xin Lin  
Guangdong Provincial People's Hospital  

Guangnan Wei  
Guangdong Provincial People's Hospital  

Jiali Lin  
Guangdong Provincial People's Hospital  

Ning Liao  
Guangdong Provincial People's Hospital  

Guochun Zhang (✉ zhangguochun@gdph.org.cn)  
Guangdong Provincial People's Hospital

Research Article

Keywords: breast cancer, HER2, second primary malignancy, incidence, SEER

DOI: https://doi.org/10.21203/rs.3.rs-565866/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The survival improvement in breast cancer (BC) renders the long-term survivors an increased probability of second primary malignancy (SPM), and thus excess mortality. Although previous evidence has indicated various predictors of SPM, little is known whether SPM incidence varies by HER2 status of first BC.

**Methods:** Based on BC patients registered between 2010-2018 in the NCI SEER database, we utilized standardized incidence ratio (SIR) and Poisson regression to quantify SPM occurrence compared with the general population. Then, adjusted for competing death risk, cumulative incidence function and Gray’s test were adopted to estimate the probability of SPM. Subsequent proportional subdistribution hazards regression was executed to identify the HER2 status impact on SPM risk. Finally, survival analysis was performed.

**Results:** A total of 409,796 first BC patients were included and 18,283 were identified with at least one SPM. The SIR of SPM after HER2+ BC was significantly lower than HER2- BC (1.03 vs 1.13; RR, 0.92; 95% CI, 0.88-0.96; p<0.001). But the predominantly declining SPM risk was only observed for second BC (RR, 0.89; 95% CI, 0.82-0.96; p=0.003) and lung and bronchus cancer (RR, 0.84; 95% CI, 0.74-0.95; p=0.007). Further competing risk analysis verified the protective effect of HER2 positivity status on SPM occurrence. The 5-year cumulative incidence of SPM following HER2+ and HER2- BC were 5.16% and 4.09%, respectively (p<0.001). In addition, among patients suffering from SPM, HER2 positivity status contributed to better overall survival.

**Conclusion:** After considering intrinsic incremental risk with age and adjusting for competing risk of death, our study demonstrated that HER2+ BC patients had lower SPM occurrence, remarkable for second BC and lung and bronchus cancer. The disparity implies the relation between SPM occurrence and therapeutic along with genetic factors underlying BC HER2 status.

**Background**

In GLOBOCAN 2020, breast cancer (BC) has become the most frequently occurring cancer and the leading cause of cancer death in women[1]. During the past decades, dramatic survival benefit has been achieved by profound understanding of BC biology, widely applied early screening, and rapid development in the systemic therapies[2–4]. One milestone of these achievements was the recognition of overexpressed human epidermal growth factor receptor 2 (HER2) as a major driver in 18–20% of BC[5, 6]. Fortunately, anti-HER2 therapies represented by trastuzumab has become the standard treatment for HER2-positive (HER2+) BC patients and substantially improved their prognosis[7–9]. However, the favorable survival outcome renders BC patient a higher probability of second primary malignancy (SPM) occurrence[10]. A recent case-control study also reported excess risk for SPM among BC survivors[11], with an adjusted standardized incidence ratio of 12.94.
Since SPM can lead to excess mortality in BC patients[12, 13], SPM occurrence and its related risk factors raised the awareness of clinicians. For example, SPM risk decreased with age[14], with an exception of lung cancer that is aging-related[15]. Negative hormone receptor was correlated with increased risk of SPM[16–18], which probably shared the same etiologic factors with first BC. It is also reported that postoperative treatment could influence the SPM occurrence. The effect of chemotherapy remains controversial[18–20], although several literatures reached the agreement that utilization of DNA-damaging chemicals led to increased incidence of SPM[21]. Radiotherapy may subject patients to a greater risk for SPM, especially lung cancer, esophageal cancer and contralateral BC[22, 23]. Conversely, hormonal therapy exhibited a protective effect from SPM occurrence[24], though patients treated with tamoxifen had an elevated risk of corpus uteri cancer[25]. In addition, genetic alteration, particularly BRCA1/2 mutation were proven to be risk factors for SPM occurrence[24, 26]. Despite massive efforts in exploring predictors of increased SPM risk, few studies have considered the effect of HER2 status[24]. It is noteworthy that no literatures reported the association between anti-HER2 therapies and SPM incidence.

This study aimed to investigate the differential SPM occurrence after first primary BC according to HER2 status, using surveillance, epidemiology, and end results (SEER) database. We used standardized incidence ratio (SIR) to profile and compare the SPM incidence between BC patients with different HER2 status. To adjust for competing death risk, subsequent competing risk analysis was conducted to explore the role of HER2 in SPM risk. We further assessed the survival outcomes according to HER2 status and whether SPM exists or not.

**Methods**

**Study Population**

SEER*Stat software (version 8.3.9) was used to obtain the SEER 18 Registries (excluding AK) Research Data (2000–2018, based on November 2020 submission), which covers approximately 27.8% of the US population. From the cases reported to this database, we incorporated female patients older than 18 years old and diagnosed with malignant BC. The malignant cases were identified based on behavior codes in ICD-O-3. Only cases with definite HER2 and HR status diagnosed between January 1, 2010 and December 31, 2018 were selected, for SEER program did not collect HER2 status of BC before the year of 2010. Cases without positive histology and active follow-up were excluded, as well as those death certificate and autopsy only cases. Besides, patients were not included if their survival months or follow-up time was shorter than 2 months or unknown, or were diagnosed with SPM within 2 months since the date of BC diagnosis in order to exclude synchronous cancers.

**Study Variables**
Patients were classified into 4 groups based on the diagnosis age: <45, 45–59, 60–74, ≥ 75 years. Four-grade system was utilized to acquire BC grades according to microscopic examination of tumor tissue. A combined stage group was derived based on clinical and pathologic information composed of primary tumor(T), regional lymph nodes(N) and distant metastasis(M). The TNM classification followed the TNM manuals published by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC), the most up-to-date edition at that time. Hormone receptor (HR) status was obtained via the immunohistochemistry test of estrogen or progesterone receptor (ER/PR)[27]. HER2 status was defined via the algorithm for deriving HER2 summary variable, according to immunohistochemistry and in situ hybridization tests[28]. The timing of the SPM and death occurrence and cause of death were also provided.

Furthermore, SEER*Stat computed the SIR to quantify the SPM incidence in first BC patients. SIR is the observed incidence of SPM among BC survivors to the expected incidence[29, 30], based on specific cancer incidence rates for the general population in SEER 18 Registries (excluding AK). The 95% CI for SIR was estimated assuming a Poisson distribution for the observed SPM numbers. SIRs of SPM following HER2-positive (HER2+) and HER2-negative (HER2-) BC patients were acquired overall and stratified by HR status, diagnosis age and malignancy site.

Statistical analysis

According to HER2 status of first BC, patient characteristics and most importantly, whether suffering from SPMs were analyzed. Pearson’s chi-square test was employed to compare the variable distribution. Due to the natural different morbidity in different cohorts, SIRs reliably manifested SPM incidence in BC survivors. With the expected numbers as an offset, Poisson regression estimated the relative risk (RR) of HER2 status, HR status and age on SPM. Since latency after first BC diagnosis varied and a large proportion of patients died before SPM occurrence, competing risk analysis was adopted to verify the risk of SPM after HER2- and HER2 + BC[31, 32]. We utilized Cumulative incidence function (CIF) to describe the occurrence, and Gray’s test to assess the statistical difference of occurrence probability. Subsequently, the hazard ratios (HRs) and 95% CIs of developing SPM after HER2 + vs. HER2- BC were calculated using proportional subdistribution hazards regression, which adjusts for competing risk of death and other significant characteristics. Regarding survival, overall survival (OS) and breast cancer-specific survival (BCSS) were calculated from the date of diagnosis of BC to the date of death, due to any causes and BC specifically. Kaplan-Meier survival analyses were utilized to estimate the OS and BCSS of BC patients based on whether SPMs exist and their intrinsic HER2 status. Log-rank tests were adopted to determine the difference significance.

All statistical analyses were performed using R version 4.0.5 software. Statistical significance was set at two-sided, with p value < 0.05 defined as statistically significant.

Results
Patient characteristics

409,796 BC patients diagnosed between 2010–2018 were selected in this study, with a median follow-up period for 44 months. HER2 + BC (N = 64,740) accounted for 15.80% of all patients, 3.54% of which (N = 2293) were reported to develop SPMs, while HER2- BC (N = 345,056) had a higher SPM incidence of 4.63% (N = 15990). Table 1 outlines the clinicopathologic characteristics and occurrence of SPM, grouped by HER2 status at first primary BC diagnosis. All factors were statistically significantly associated with HER2 status (p < 0.001) based on Pearson's chi-square test. For HER2 + BC patients, 11592 (17.91%) women were diagnosed aged < 45 and 26282 (40.60%) aged between 45–59, accounting for significantly higher proportions than those with HER2- BC.

Table 1 Patients Characteristics
| Characteristics                        | HER2 Positive       | HER2 Negative      | \( p \)-value |
|----------------------------------------|---------------------|--------------------|---------------|
|                                        | 64,740 (100.00)     | 345,056 (100.00)   |               |
| Age (years), n (%)                     |                     |                    | < 0.001       |
| < 45                                   | 11592 (17.91)       | 38307 (11.10)      |               |
| 45–59                                  | 26282 (40.60)       | 117291 (33.99)     |               |
| 60–74                                  | 19906 (30.75)       | 133339 (38.64)     |               |
| \( \geq \) 75                         | 6960 (10.75)        | 56119 (16.26)      |               |
| Grade, n (%)                           |                     |                    | < 0.001       |
| Well differentiated                    | 3030 (4.68)         | 88356 (25.61)      |               |
| Moderately differentiated              | 22762 (35.16)       | 152963 (44.33)     |               |
| Poorly differentiated/Undifferentiated | 35310 (54.54)       | 91326 (26.47)      |               |
| Unknown                                | 3638 (5.62)         | 12411 (3.60)       |               |
| Stage, n (%)                           |                     |                    | < 0.001       |
| 0/I                                    | 24020 (37.10)       | 181579 (52.62)     |               |
| II                                     | 23874 (36.88)       | 107334 (31.11)     |               |
| III                                    | 9788 (15.12)        | 34492 (10.00)      |               |
| IV                                     | 4997 (7.72)         | 13937 (4.04)       |               |
| Unknown                                | 2061 (3.18)         | 7714 (2.24)        |               |
| HR status, n (%)                       |                     |                    | < 0.001       |
| Negative                               | 19162 (29.6)        | 45841 (13.29)      |               |
| Positive                               | 45578 (70.4)        | 299215 (86.71)     |               |
| With SPM, n (%)                        |                     |                    | < 0.001       |
| Yes                                    | 2293 (3.54)         | 15990 (4.63)       |               |
| No                                     | 62447 (96.46)       | 329066 (95.37)     |               |

Abbreviations: HR hormone receptor, HER2 human epidermal growth factor receptor 2

Besides, HER2 + BC were more likely to have advanced grade and stage, and negative HR status. However, SPMs were remarkably less common in HER2 + BC patients, despite their clinicopathologic characteristics reflect more aggressive clinical courses.

**Profile of SPM incidence**
18,283 patients were diagnosed with at least one SPM after 2 months of first BC diagnosis, with 19,297 SPMs overall, which was significantly more than the 17,346.64 expected cases based on the rates in the general population (SIR = 1.11; 95% CI 1.10–1.13). As listed in Table 2, compared with the general population, SPM incidence was

**Table 2** Standardized incidence ratios (SIRs) of second primary malignancy (SPM) only significantly elevated following HER2- BCs, of which SIR was 1.13 (95% CI 1.11-1.14; p<0.05). Based on the Poisson regression, the RR of SPMs following HER2+ versus HER2- BCs was 0.92 (95% CI 0.88-0.96; p<0.001). The results were consistent in both HR status subgroups. Regarding HR status, the SPM risk for HR- versus HR+ BC patients was significantly increased, with an RR of 1.14 (95% CI 1.11-

|                | HER2+   | HER2-   | HER2+ versus HER2- | p-value | RR (95% CI) |
|----------------|---------|---------|--------------------|---------|-------------|
| **All patients** | SIR     | 95% CI  | SIR                | 95% CI  | RR (95%CI)  | p-value |
|                | 1.03    | 0.99-1.07 | 1.13* | 1.11-1.14 | 0.92 (0.88-0.96) | <0.001 |
| **HR status**   |         |         |                    |         |             |         |
| Positive        | 1.02    | 0.98-1.07 | 1.10* | 1.09-1.12 | 0.94 (0.88-1.00) | <0.001 |
| Negative        | 1.04    | 0.97-1.12 | 1.30* | 1.24-1.35 | 0.80 (0.74-0.88) | <0.001 |
| **Age(years)**  |         |         |                    |         |             |         |
| <45             | 1.99*   | 1.75-2.44 | 2.12* | 1.99-2.25 | 0.94 (0.82-1.07) | 0.347 |
| 45-59           | 1.13*   | 1.06-1.21 | 1.28* | 1.25-1.32 | 0.88 (0.82-0.95) | <0.001 |
| 60-74           | 0.87*   | 0.81-0.93 | 1.01  | 0.99-1.04 | 0.86 (0.80-0.92) | <0.001 |
| ≥75             | 0.94    | 0.85-1.04 | 1.07* | 1.04-1.1 | 0.88 (0.79-0.98) | 0.02  |

1.16;p<0.001). Among BC molecular subtypes, the uppermost SIR of 1.30 (95% CI 1.24-1.35) belongs to the triple negative BC. In different age subgroups, the significantly lower SPM incidence after HER2+ BCs was only consistent in patients older than 44 years. The SPM risk also decreased as patients age. It is noteworthy that HER2+ BC patients aged 60-74 had a significantly SPM incidence reduction than the general population (SIR, 0.87; 95% CI 0.81-0.93).

The impact of HER2 status on SPM risk may differ by specific SPM types, thus SPM occurrence in different sites was then profiling. The most frequent SPM sites were female breast (N=5,499 [28.50%]), followed by lung and bronchus (N=2,388 [12.38%]),
colon (N=1129 [5.85%]), corpus uteri (N=1090 [5.65%]) and thyroid (N=968 [5.02%]). Number of patients developing SPM and the SIRs of different SPM types following HER2+ vs. HER2- BC are exhibited in Fig. 1. For HER2+ BC patients, SIRs significantly greater than 1 were only observed with second thyroid cancer, renal carcinoma, leukemia and gastric cancer (site-specific SIRs were 2.38, 1.58, 1.69 and 1.51, respectively; all p <0.05). Except gastric cancer, incidence of the other three SPMs in HER2- BC survivors also significantly exceed the general population. For most SPM sites, including female breast, lung and bronchus, colon, melanoma, pancreas, SPMs with higher occurrence rates than the general population were only observed among HER2- BC patients. Poisson regression was used again to estimate different second malignancy risks according to different HER2 status. Fig. 2 demonstrated the forest plots visualizing the relative risks of HER2 positive status for SPM occurrence. Notably, only for second primary malignancies in female breast (RR, 0.89; 95% CI, 0.82-0.96; p=0.003) and lung and bronchus (RR, 0.84; 95% CI, 0.74-0.95; p=0.007), the risks were significantly reduced after HER2+ BC in comparison to HER2- BC patients. The risk was marginally reduced for second corpus uteri cancer (RR, 0.83; 95% CI, 0.69-0.99; p=0.041). In addition, HER2 positive status was revealed to be a risk factor for second thyroid malignancy occurrence (RR, 1.22; 95% CI, 1.04-1.42; p=0.015).

**Competing risk analysis**

When estimating the SPM incidence, occurrence of death can compete and should be taken into account by competing risk analysis. Fig. 3 depicted the cumulative incidence of SPMs and deaths via CIF. The 5-year cumulative incidence of SPMs following first HER2- and HER2+ BC were 5.16% and 4.09%, respectively. HER2- BC patients had a markedly higher cumulative SPM incidence than HER2+ BC patients (p<0.001), and on the contrary, lower significantly death incidence (p<0.001). To understand whether the difference of SPM cumulative incidence is solely due to the HER2 status, subdistribution hazard function was performed, as shown in Table 3. Univariate regression analysis indicated that not only HER2 status, but also age, grade, stage and HR status were correlated with SPM risk. Multivariate regression analysis further screened HER2 status and diagnosis age as independent risk factor for SPM. HER2 positive status significantly reduced the total SPM risk (sdHR, 0.86; 95% CI, 0.82-0.90; p<0.001), in accordance with aforementioned results. However, the inconsistence was that SPM risk increased as patients diagnosed at older age (p<0.001), and HR status did not differ statistically in SPM risk (p=0.28).

In addition, multivariate proportional subdistribution hazards regression was

**Table 3** Univariate and multivariate proportional subdistribution hazard regression of second primary malignancy (SPM) in breast cancer patients.
| Characteristics      | Univariate |                   |         | Multivariate |                   |         |
|----------------------|------------|-------------------|---------|--------------|-------------------|---------|
|                      |            | sdHR (95% CIs)    | p-value | sdHR (95% CIs)| p-value          |         |
| **Age (years)**      |            |                   |         |              |                   |         |
| <45                  | Reference  |                   |         | Reference    |                   |         |
| 45-59                | 1.42 (1.33, 1.51) | <0.001       | 1.40 (1.31, 1.49) | <0.001       |         |
| 60-74                | 2.15 (2.02, 2.28) | <0.001       | 2.09 (1.96, 2.22) | <0.001       |         |
| ≥75                  | 2.56 (2.39, 2.74) | <0.001       | 2.49 (2.32, 2.67) | <0.001       |         |
| **Grade**            |            |                   |         |              |                   |         |
| Well differentiated  | Reference  |                   |         | Reference    |                   |         |
| Moderately differentiated | 0.93 (0.90, 0.97) | <0.001  | 0.98 (0.94, 1.02) | 0.29       |         |
| Poorly differentiated/Undifferentiated | 0.81 (0.77, 0.84) | <0.001  | 0.94 (0.89, 0.98) | 0.0043      |         |
| Unknown              | 0.80 (0.74, 0.87) | <0.001  | 0.91 (0.84, 0.99) | 0.024       |         |
| **Stage**            |            |                   |         |              |                   |         |
| 0/I                  | Reference  |                   |         | Reference    |                   |         |
| II                   | 0.91 (0.88, 0.94) | <0.001  | 0.98 (0.95, 1.02) | 0.31       |         |
| III                  | 0.91 (0.87, 0.96) | <0.001  | 1.03 (0.97, 1.08) | 0.36       |         |
| IV                   | 0.67 (0.61, 0.74) | <0.001  | 0.73 (0.66, 0.80) | <0.001      |         |
| Unknown              | 0.83 (0.74, 0.93) | 0.0016  | 0.85 (0.76, 0.95) | 0.005       |         |
| **HR status**        |            |                   |         |              |                   |         |
| Negative             | Reference  |                   |         | Reference    |                   |         |
| Positive             | 1.11 (1.06, 1.15) | <0.001  | 0.98 (0.93, 1.02) | 0.28       |         |
| **HER2 status**      |            |                   |         |              |                   |         |
| Negative             | Reference  |                   |         | Reference    |                   |         |
| Positive             | 0.77 (0.74, 0.80) | <0.001  | 0.86 (0.82, 0.90) | <0.001      |         |

Abbreviations: sdHR subdistribution hazard ratios, HR hormone receptor, HER2 human epidermal growth factor receptor 2

performed according to different SPM sites. For second primary BC, as well as lung and bronchus cancer, SPM risk decreased significantly after first HER2+ BC, with sdHR of 0.82 (95% CI, 0.75-0.89; p < 0.001) and 0.78 (95% CI 0.68-0.90; p < 0.001) respectively. Whereas, little variance on second corpus uteri cancer risk
were shown between different HER2 status BC patients (sdHR, 0.79; 95% CI, 0.66-0.95; p=0.014), and no difference on second thyroid cancer risk (sdHR, 1.18; 95% CI, 1.00-1.39; p=0.053).

**Kaplan-Meier survival analysis**

Finally, the impact of SPM and HER2 status on OS and BCSS was analyzed (Fig. 4). Among the 18,283 BC patients with SPMs, 1828 (10.00%) died of BC, whereas 3645 (19.94%) patients died of other causes. In line with previous studies, SPM was associated with prominently worse OS (HR, 2.00; 95% CI, 1.93-2.08; p<0.0001), but sightly worsen BCSS (HR, 1.09; 95% CI, 1.03-1.14; p=0.0012). The 5-year OS probability was 74.4% (p=0.004) and 85.5% (p<0.001) for BC patients with/without SPMs. We also found a substantial difference in BCSS between HER2- and HER2+ BC patients (HR, 0.79; 95% CI, 0.77-0.82; p<0.0001) but a minor disparity in OS (HR, 0.97; 95% CI, 0.95-1.00; p=0.0221). Better survival outcomes favored negative HER2 status. For BC patients followed by SPMs, reversely, positive HER2 status was associated with superior OS (5-year OS, 76.2% vs 74.2%; p=0.0011). However, no variance was shown regrading BCSS, indicating the survival difference may be attributed to other causes of death concerning SPM.

**Discussion**

In our study, we mainly focused on the association between SPM occurrence and HER2 status of first BC. Significantly increased incidence of SPM was demonstrated in HER2- BC patients. In 2015, Raffaella et al. reported that HER2 positivity was associated with increased risk of secondary digestive system and thyroid cancer[24]. Incorporating 305 cases and 1,525 control patients, this study was limited by small sample sizes. For the first time, two different methods were performed to explore the risk factors for SPM incidence. On the one hand, older age is associated with intrinsic incremental cancer risk. And HER2 status varied with age according to our baseline characteristics analysis. Therefore, SPM risk and effect of HER2 status were quantified using standardized incidence ratios (SIRs) and Poisson regression, by introducing age-specific rates in the general population as external reference. On the other hand, we further executed competing risk analysis to verify the impacts of risk factors on SPM occurrence, considering death as a competing risk. Eventually, two approaches yielded similar result that remarkable SPM risk difference existed between HER2+ and HER2- BC patients.

However, apparent discrepancy was presented for age and HR status. In the latter proportional subdistribution hazards regression, the SPM risk increased when BC patients were diagnosed at older age. But if we take the natural incremental cancer risk with age into account, totally contrary result was obtained that SPM risk declined with age. It seemed more reliable and may be attributable to the genetic predisposition of cancer in young BC patients and probable prolonged survival period. We also discovered an elevated risk of SPM among HR- BC patients as reported by previous studies[14, 17], which may due to common genetic determinants and limited treatment. Nevertheless, after adjusting for the death risk, no statistically significant result was observed between HR+ and HR- BC patients. We suspect that the non-negligible occurrence of death precluded the occurrence of SPMs, probably contributing to
an overestimation of SPM occurrence in HR- BC patients. Age could also be regarded as a confounder, since HR negative status was more common in younger BC patients[33].

Although HER2- BC was not so aggressive as HER2+ BC, the higher incidence of SPM makes it a new concern for BC survivors. As above mentioned, compared with HER2+ BC, HER2- BC patients had superior BCSS in all patients, but worse OS in patients followed by SPM. To improve the OS of HER2- BC patients, it is important to find out the potential contributing factors that are relevant to HER2 status.

In recent decades, HER2 status has been an established target in BC therapy. Biologically, HER2 exists as a driving factor in various tumor types derived from epithelia, represented by BC, non-small-cell lung cancer[34, 35], gastric and gastroesophageal junction cancers[36, 37]. It was further confirmed by the fact that HER2 overexpression or gene amplification were detected in a variety of human malignancies including lung[38], gastric[39], ovarian[40], biliary tract[41] and colorectal cancers[42]. In therapeutic application, anti-HER2 therapies have already shown efficacy in HER2-positive advanced gastric cancers[36, 43, 44]. Therefore, we speculate that when HER2+ patients undertook anti-HER2 treatment for BC, these targeting therapies would probably simultaneously extinguish and eliminate latent HER2+ transformed cells in other systems. As a result, the SPM incidence decreased after HER2+ BC due to the HER2-targeted treatment. It is known that more than two decades have passed since the approval of the first anti-HER2 targeted therapy trastuzumab by FDA in 1998. And HER2-targeted treatment has become the standard care in managing HER2+ BC patients all over the world. Hence, recent calendar year and HER2 positivity diagnosis have been used as a crude proxy to support this hypothesis. Besides anti-HER2 therapy, HER2+ BC patients were more likely to received adjuvant chemotherapy[45, 46], which may also contribute to the declining SPM incidence.

As for the intrinsic risk factors of SPM, shared genetic predisposition associated with BC HER2 status is inevitable. It has been reported that pathogenic germline variants were exhibited in 8% of adult cancer cases[47]. Genomic alterations are also reported to be incriminated towards HER2+ BC[48, 49]. Moreover, several genes such as FCRLM1, BLK and IHGD were indicative of the development of SPMs among BC patients[48, 49]. It led to the assumption that some unique intrinsic genetic variants existed in BC patients may be a natural inclination for the SPMs. Indirect support for the hypothesis can be gleaned from the findings that higher proportion of HER2 positivity status was observed in BC patients carrying BRCA2 mutations, and meanwhile, BRCA2 carriers were less likely to be diagnosed with SPMs[50]. In summary, the SPM risk reduction after HER2+ BC may be attributable to the widespread anti-HER2 treatment combined with chemotherapy, as well as genetic susceptibility. More investigation about therapeutic and inherent factors should be conducted to reveal the disparity between different BC HER2 status.

The differential SPM occurrence following HER2+ and HER2- BC was comprehensively profiled in this context. It was based on a large population cohort from SEER program, thus minimizing the sampling error and ensuring the quality of the data. However, there were still some limitations. First, some metastasis and relapse may be mistaken as SPM. Although we excluded the cases within 2 months since BC diagnosis to avoid synchronous cancers. Second, because of data incompleteness, we could not
analyze effects of adjuvant treatment, especially anti-HER2 therapies. Third, data on some potential risk factors was not available, such as smoking, alcohol use and body mass index. More researches with detailed information on treatment delivery, genetic variants and other confounders are needed to reveal the disparity.

In conclusion, SPM incidence significantly declined after HER2+ BC, demonstrated by different quantitative tools including SIR and competing risk model. The OS deterioration in HER2- BC patients accompanied by SPM indicated the requirement to explain this disparity, with the aim of reducing SPM risk. We suggested that the differential SPM occurrence could be attributable to HER2-targeted therapy combined with chemotherapy, and inherent genetic factors, both of which are closely related to HER2 status of first BC. Further studies are required to prove this plausible hypothesis.

Declarations

Acknowledgements

The authors acknowledge the efforts of the Surveillance, Epidemiology and End Results (SEER) Program tumor registries in providing detailed information.

Authors’ contributions

GZ, NL and XYL designed the study. XYL, XL and GW contributed to the data acquisition, statistical analysis and interpretation. XYLand JL drafted the manuscript. GZ and NL revised the article. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by Guangzhou Municipal Science and Technology Project (201804010430) and Natural Science Foundation of Guangdong Province (2018A030313292). The funding body had no roles in the design of the study, and collection, analysis and interpretation of data, writing of the manuscript or the decision for paper publication.

Availability of data and materials

The dataset supporting the conclusions of this article is available in the SEER*Stat software (version 8.3.9) after providing submit request at https://seer.cancer.gov/seertrack/data/request/.

Ethics approval and consent to participate

Since SEER database is publicly available, this study was exempt from ethical approval or patients’ consent.

Consent for publication
Informed consent for publication was obtained from all authors.

Competing interests

The authors declared that they have no competing interests.

Abbreviations

HRhormonereceptor, HER2 human epidermal growth factor receptor 2, SIR standardized incidence ratio, CI, confidence interval, RR relative risk, *p value<0.05

References

1. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2021.
2. Waks AG, Winer EP: Breast Cancer Treatment: A Review. JAMA 2019, 321(3):288-300.
3. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J et al: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet 2018, 391(10125):1023-1075.
4. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37(9):1217-1226.
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
6. Gutierrez C, Schiff R: HER2: biology, detection, and clinical implications. Archives of pathology & laboratory medicine 2011, 135(1):55-62.
7. Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L et al: 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London, England) 2017, 389(10075):1195-1205.
8. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Jr, Martino S, Rastogi P, Gralow J, Swain SM et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014, 32(33):3744-3752.
9. Rimawi MF, Schiff R, Osborne CK: Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine 2015, 66(1):111-128.
10. Molina-Montes E, Requena M, Sanchez-Cantalejo E, Fernandez MF, Arroyo-Morales M, Espin J, Arrebola JP, Sanchez MJ: Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. *Gynecol Oncol* 2015, 136(1):158-171.

11. Li Z, Wang K, Shi Y, Zhang X, Wen J: Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. *Int J Cancer* 2020, 146(2):352-362.

12. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *The Lancet* 2005, 366(9503):2087-2106.

13. Katuwal S, Jousilahti P, Pukkala E: Causes of death among women with breast cancer: A follow-up study of 50 481 women with breast cancer in Finland. *International journal of cancer* 2021.

14. Rusner C, Wolf K, Bandemer-Greulich U, Engel J, Stegmaier C, Holleczeck B, Schubert-Fritschle G, Tillack A, Stang A: Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. *Breast cancer research : BCR* 2014, 16(5):452.

15. Raymond JS, Hogue CJ: Multiple primary tumours in women following breast cancer, 1973-2000. *Br J Cancer* 2006, 94(11):1745-1750.

16. Qian X, Jia H, Zhang Y, Ma B, Qin G, Wu Z: Risk factors and prediction of second primary cancer in primary female non-metastatic breast cancer survivors. *Aging* 2020, 12(19):19628-19640.

17. Schonfeld SJ, Curtis RE, Anderson WF, Berrington de González A: The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. *Cancer Causes & Control* 2012, 23(10):1721-1728.

18. Li D, Weng S, Zhong C, Tang X, Zhu N, Cheng Y, Xu D, Yuan Y: Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer. *Frontiers in oncology* 2019, 9:1426.

19. Wei JL, Jiang YZ, Shao ZM: Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. *Int J Clin Oncol* 2019, 24(8):934-940.

20. Jeyakumar A, Chua T, Lam A, Gopalan V: The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations. *Critical reviews in oncology/hematology* 2020, 152:102989.

21. Wei J, Jiang Y, Shao Z: Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. *International journal of clinical oncology* 2019, 24(8):934-940.

22. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK: Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. *Breast* 2017, 35:122-129.

23. Schaapveld M, Visser O, Louwman M, de Vries E, Willems P, Otter R, van der Graaf W, Coebergh J, van Leeuwen F: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008, 26(8):1239-1246.
24. Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, Ferri P, Napolitano M, Federico M, Sacchi S: Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. *J Breast Cancer* 2015, 18(4):378-385.

25. Andersson M, Jensen M, Engholm G, Henrik Storm H: Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. *Acta oncologica (Stockholm, Sweden)* 2008, 47(4):755-764.

26. Agarwal S, Pappas L, Matsen C, Agarwal J: Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy. *Cancer medicine* 2020, 9(21):8043-8052.

27. Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S, Fitzgibbons P, Francis G, Goldstein N, Hayes M *et al.* American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *Archives of pathology & laboratory medicine* 2010, 134(6):907-922.

28. Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J, Bilous M, Ellis I, Fitzgibbons P, Hanna W *et al.* Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol* 2018, 36(20):2105-2122.

29. Liddell F: Simple exact analysis of the standardised mortality ratio. *J Epidemiol Community Health* 1984, 38(1):85-88.

30. Yasui Y, Liu Y, Neglia J, Friedman D, Bhatia S, Meadows A, Diller L, Mertens A, Whitton J, Robison L: A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. *Am J Epidemiol* 2003, 158(11):1108-1113.

31. Kim HT: Cumulative incidence in competing risks data and competing risks regression analysis. *Clin Cancer Res* 2007, 13(2 Pt 1):559-565.

32. Scrucca L, Santucci A, Aversa F: Regression modeling of competing risk using R: an in depth guide for clinicians. *Bone Marrow Transplant* 2010, 45(9):1388-1395.

33. Anderson W, Chatterjee N, Ershler W, Brawley O: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. *Breast Cancer Res Treatment* 2002, 76(1):27-36.

34. Hotta K, Yanai H, Ohashi K, Ninomiya K, Nakashima H, Kayatani H, Takata M, Kiura K: Pilot evaluation of a HER2 testing in non-small-cell lung cancer. *J Clin Pathol* 2020, 73(6):353-357.

35. Kuyama S, Hotta K, Tabata M, Segawa Y, Fujiwara Y, Takigawa N, Kiura K, Ueoka H, Eguchi K, Tanimoto M: Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. *J Thorac Oncol* 2008, 3(5):477-482.
36. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T *et al.*: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *The Lancet* 2010, 376(9742):687-697.

37. Tanner M, Hollmen M, Junnttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E *et al.*: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase llalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann Oncol* 2005, 16(2):273-278.

38. Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G, Bosari S: HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2003, 9:3645-3652.

39. Abrahao-Machado L, Scapulatempo-Neto C: HER2 testing in gastric cancer: An update. *World journal of gastroenterology* 2016, 22(19):4619-4625.

40. Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science (New York, NY)* 1989, 244(4905):707-712.

41. Nam A, Kim J, Cha Y, Ha H, Park J, Bang J, Jin M, Lee K, Kim T, Han S *et al.*: Therapeutic implication of HER2 in advanced biliary tract cancer. *Oncotarget* 2016, 7(36):58007-58021.

42. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz H, McCall S, Penault-Llorca F, Srock S, Bardelli A, Trusolino L: Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. *Annals of oncology : official journal of the European Society for Medical Oncology* 2018, 29(5):1108-1119.

43. Patel TH, Cecchini M: Targeted Therapies in Advanced Gastric Cancer. *Curr Treat Options Oncol* 2020, 21(9):70.

44. Oh DY, Bang YJ: HER2-targeted therapies - a role beyond breast cancer. *Nat Rev Clin Oncol* 2020, 17(1):33-48.

45. Romond E, Perez E, Bryant J, Suman V, Geyer C, Davidson N, Tan-Chiu E, Martino S, Paik S, Kaufman P *et al.*: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *The New England journal of medicine* 2005, 353(16):1673-1684.

46. Swain S, Baselga J, Kim S, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J, Schneeweiss A, Heeson S *et al.*: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *The New England journal of medicine* 2015, 372(8):724-734.

47. Huang KL, Mashl RJ, Wu Y, Ritter DL, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N *et al.* Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell* 2018, 173(2):355-370 e314.

48. Armakolas A, Stathopoulos G, Nezos A, Theos A, Stathaki M, Koutsilieris M: Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients. *Oncology reports* 2012, 28(6):2255-2263.
Figures

Figure 1

Standardized incidence ratios (SIRs) and patient numbers of second primary malignancies (SPM) in specific sites.
**Figure 2**

Site-specific Standardized incidence ratios (SIRs) and relative risks of developing second primary malignancies (SPM) after HER2+/HER2- BCs.

| SPM Sites            | Number (%) | SIR  | SIR  | HER2+ versus HER2- RR (95% CI) | p-Value |
|----------------------|------------|------|------|--------------------------------|---------|
| Breast               | 5499 (28.50)| 0.99 | 1.12*| 0.89 (0.82,0.96)              | 0.003   |
| Lung and Bronchus    | 2388 (12.37)| 0.95 | 1.13*| 0.84 (0.74,0.95)              | 0.007   |
| Colon                | 1129 (5.85) | 1.05 | 1.10*| 0.95 (0.80,1.13)              | 0.580   |
| Corpus Uteri         | 1090 (5.65) | 0.85 | 1.02 | 0.83 (0.69,0.99)              | 0.041   |
| Thyroid              | 968 (5.02)  | 2.38*| 1.95*| 1.22 (1.04,1.42)              | 0.015   |
| Melanoma of the Skin | 746 (3.87)  | 1.15 | 1.18*| 0.98 (0.79,1.19)              | 0.814   |
| Lymphoma             | 663 (3.44)  | 0.91 | 0.97 | 0.94 (0.74,1.17)              | 0.564   |
| Pancreas             | 632 (3.28)  | 0.99 | 1.21*| 0.82 (0.63,1.04)              | 0.117   |
| Kidney               | 603 (3.12)  | 1.58*| 1.45*| 1.09 (0.87,1.35)              | 0.445   |
| Leukemia             | 559 (2.90)  | 1.69*| 1.44*| 1.18 (0.93,1.46)              | 0.157   |
| Ovary                | 425 (2.20)  | 0.80 | 1.05 | 0.77 (0.56,1.02)              | 0.081   |
| Urinary Bladder      | 387 (2.01)  | 0.82 | 1.08 | 0.76 (0.54,1.04)              | 0.098   |
| Rectum               | 276 (1.43)  | 1.03 | 1.03 | 1.01 (0.71,1.39)              | 0.963   |
| Myeloma              | 259 (1.34)  | 0.82 | 1.07 | 0.77 (0.51,1.11)              | 0.181   |
| Stomach              | 236 (1.22)  | 1.51*| 1.13 | 1.34 (0.96,1.84)              | 0.076   |
| Brain                | 150 (0.78)  | 1.17 | 0.93 | 1.25 (0.80,1.88)              | 0.304   |
| Liver                | 144 (0.75)  | 0.73 | 0.89 | 0.82 (0.48,1.33)              | 0.454   |
| Cervix Uteri         | 125 (0.65)  | 0.63*| 0.74*| 0.85 (0.50,1.36)              | 0.511   |
| **All Sites**        | **19297**   | **1.03** | **1.13** | **0.92 (0.88,0.96)** | **<0.001** |

*indicates the significance of p value < 0.05.
Figure 3

Cumulative incidence curves for second primary malignancies and deaths in HER2+ and HER2- breast cancer patients.
**Figure 4**

Survival curves of OS and BCSS based on (a, b) SPM occurrence; (c, d) HER2 status in all patients and (e, f) HER2 status in patients with SPMs.